修订版成人T细胞白血病-淋巴瘤国际共识会议报告
该共识报告由ATL领域的研究者与临床医生在2017年3月于日本东京召开的第18届国际人类逆转录病毒学会议(聚焦人类T淋巴细胞病毒及相关逆转录病毒)上,基于对当前临床实践证据的回顾,更新了2009年版共识,重点涉及皮肤型ATL亚型分类、侵袭性ATL的中枢神经系统病变、老年或不适合移植患者的管理,以及纳入 upfront 异基因造血干细胞移植和新型药物的治疗策略。由于临床证据质量较低,采用了最佳实践方法,并由共同作者达成共识声明(同意率>90%)。共识强调需要开展更多临床试验以开发ATL的新型标准疗法。
要点
- 皮肤型ATL亚型分类、侵袭性ATL中枢神经系统病变、老年或不适合移植患者管理是本次共识的新重点。
- 治疗策略纳入 upfront 异基因造血干细胞移植和新型药物。
- 因临床证据质量较低,采用最佳实践方法,共识声明由共同作者达成(同意率>90%)。
核心结论
- 该专家共识强调需要开展更多临床试验以开发治疗ATL的新型标准疗法。
研究设计与样本
- ATL研究者与临床医生于2017年3月在日本东京召开的第18届国际人类逆转录病毒学会议(聚焦人类T淋巴细胞病毒及相关逆转录病毒)上,回顾当前临床实践证据并更新共识。
- 因临床证据质量较低,采用最佳实践方法,共识声明由共同作者达成(同意率>90%)。
主要发现
- 本次共识更新重点包括皮肤型ATL的亚型分类、侵袭性ATL的中枢神经系统病变、老年或不适合移植患者的管理,以及纳入 upfront 异基因造血干细胞移植和新型药物的治疗策略。
关键数值与推荐
- 共识声明由共同作者达成,同意率>90%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因临床证据质量较低,采用最佳实践方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical features and prognosis. ATL remains a challenging disease as a result of its diverse clinical features, multidrug resistance of malignant cells, frequent large tumor burden, hypercalcemia, and/or frequent opportunistic infection. In 2009, we published a consensus report to define prognostic factors, clinical subclassifications, treatment strategies, and response criteria. The 2009 consensus report has become the standard reference for clinical trials in ATL and a guide for clinical management. Since the last consensus there has been progress in the understanding of the molecular pathophysiology of ATL and risk-adapted treatment approaches. METHODS: Reflecting these advances, ATL researchers and clinicians joined together at the 18th International Conference on Human Retrovirology-Human T-Lymphotropic Virus and Related Retroviruses-in Tokyo, Japan, March, 2017, to review evidence for current clinical practice and to update the consensus with a new focus on the subtype classification of cutaneous ATL, CNS lesions in aggressive ATL, management of elderly or transplantation-ineligible patients, and treatment strategies that incorporate up-front allogeneic hematopoietic stem-cell transplantation and novel agents. RESULTS: As a result of lower-quality clinical evidence, a best practice approach was adopted and consensus statements agreed on by coauthors (> 90% agreement). CONCLUSION: This expert consensus highlights the need for additional clinical trials to develop novel standard therapies for the treatment of ATL.
引用
- Cook LB, Fuji S, Hermine O, et al. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019. PMID: 30657736. doi:10.1200/JCO.18.00501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。